Tiziana develops novel treatment for COVID-19 patients using anti-interleukin-6-receptor mAbs


Company has filed patent application in support of treatment of COVID-19 utilizing anti-il6r via inhaled delivery

Tiziana develops novel treatment for COVID-19 patients using anti-interleukin-6-receptor mAbs

Tiziana Life Sciences, a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, has developed investigational new technology to treat COVID-19 infections, which consists of direct delivery of anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs using a handheld inhaler or nebuliser.

Development of this novel technology is a step forward toward expediting development of TZLS-501, a fully-human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with COVID-19 (SARS-CoV-2) coronavirus.

The company believes the technology could also be applicable for use with other FDA approved mAbs and drugs. The company has submitted a provisional patent application for the delivery technology.

“Direct delivery of anti-IL-6R mAb to the lungs using a portable handheld inhaler or nebuliser is a rapid and immediate therapy for children and adults infected with COVID-19."

"Importantly, this treatment with our fully human anti-IL-6R mAb (TZLS-501) has the potential to be a long-term therapy to halt progression and reduce mortality in patients with COVID-19, as a portion of the population may not opt to utilise a vaccine,” said Gabriele Cerrone, Chair of Tiziana Lifesciences.

Patients infected with COVID-19 are known to develop an uncontrolled immune response (“cytokine storm”), which results in excessive production of pro-inflammatory cytokines and other proteins such as interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-a) and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), which in turn causes severe damage to lung tissue resulting in respiratory failure and eventually death.

Among these cytokines, IL-6 seems to be one of the major culprits underlying coronavirus-mediated respiratory failure. Early clinical studies conducted by doctors in China suggest that anti-IL6R mAbs may be used in clinical practice to treat COVID-19. Consequently, China’s National Health Commission has recommended the use of Roche’s blockbuster drug, Actemra and Sanofi’s Kevzera for treatment of patients infected with COVID-19.

Excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with the severe lung damage commonly observed with COVID-19 infections and acute respiratory distress syndrome (ARDS).

Tiziana believes TZLS-501 (anti-IL6R) combined with this newly introduced inhalation technology may rapidly inhibit inflammation in lungs and in combination with intravenous administration may deplete circulating levels of IL-6 and potentially halt progression of COVID-19-mediated lung damage and death.

“The filing of this comprehensive provisional patent application covering treatment with our anti-IL-6R mAb, as well as prophylactic intervention with a vaccine candidate, designed from Spike (S) protein of COVID-19, is an important step in finding a solution to the current pandemic."

Sign up for your free email newsletter

"We look forward to providing updates on the development of this product candidate and its introduction into clinical trials in a real-world setting,” said Dr Kunwar Shailubhai, CEO & CSO of Tiziana Life Sciences.